Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2009

View Archived Issues

Kowa claims novel G-protein-coupled receptor 40 and 120 agonists as antidiabetic agents

Novel vanilloid receptor ligands for the treatment of pain disclosed by Amgen

NeuroSearch presents novel potassium channel modulators for the treatment of respiratory disorders

GlaxoSmithKline claims novel compounds for the treatment of anemia

Amgen presents p38 protein kinase inhibitors for the treatment of rheumatoid arthritis

Second-generation FLT3 inhibitor developed as a candidate for acute myeloid leukemia therapy

Preclinical studies of ARRY-520 aid in selecting target cancers

Ajinomoto and Dainippon granted approval for additional indication for Niflec and Gasmotin

AcelRx initiates phase II cancer breakthrough pain program

First-in-man results with IDX-84, data on other HCV treatments from Idenix presented

OPERA-1 interim results show potent antiviral activity of TMC-435 against hepatitis C

Perlegen and Celera sign license agreement for cardiovascular biomarkers

CHMP issues positive opinion for AstraZeneca's oral anticancer drug, Iressa

FDA approves IND for ConjuGon's phase Ib C-1205 trial

Zoledronic acid may reduce androgen-deprivation-induced bone loss in prostate cancer patients

FDA extends review timeline for Onglyza NDA

Promising preclinical results seen with new HCV protease inhibitors EA-058, EA-063

Genesis changes name to Jiangbo Pharmaceuticals

Selective inhibitors of anaplastic lymphoma kinase show in vitro and in vivo antitumor activity

Novo Nordisk receives positive CHMP opinion on Victoza

Nycomed's Instanyl receives positive CHMP opinion for cancer pain

Targacept initiates phase II TC-5214 study in patients with resistant hypertension

Pfizer and University College London to collaborate on stem cell-based therapies for AMD

Health Canada approves Cangene's hepatitis B therapeutic HepaGam B for second indication

Simponi receives FDA approval as once-monthly anti-TNF for RA

Icagen completes enrollment in phase II study of senicapoc in allergic asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...